198 related articles for article (PubMed ID: 22221634)
1. Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?
Hillner BE; Tosteson AN; Song Y; Tosteson TD; Onega T; Goodman DC; Siegel BA
J Am Coll Radiol; 2012 Jan; 9(1):33-41. PubMed ID: 22221634
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effective PET investigations in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effective PET scans in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
[TBL] [Abstract][Full Text] [Related]
4. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
Facey K; Bradbury I; Laking G; Payne E
Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
[TBL] [Abstract][Full Text] [Related]
5. Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer.
Onega T; Tosteson TD; Wang Q; Hillner BE; Song Y; Siegel BA; Tosteson AN
J Am Coll Radiol; 2012 Sep; 9(9):635-42. PubMed ID: 22954545
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of PET in oncology.
Rohren EM; Turkington TG; Coleman RE
Radiology; 2004 May; 231(2):305-32. PubMed ID: 15044750
[TBL] [Abstract][Full Text] [Related]
8. Pattern of Imaging after Lung Cancer Resection. 1992-2005.
Sharma G; Nishi SP; Lin YL; Kuo YF; Goodwin JS; Riall TS
Ann Am Thorac Soc; 2016 Sep; 13(9):1559-67. PubMed ID: 27243464
[TBL] [Abstract][Full Text] [Related]
9. Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.
Healy MA; Yin H; Reddy RM; Wong SL
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26903519
[TBL] [Abstract][Full Text] [Related]
10. Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT.
Karantanis D; Subramaniam RM; Mullan BP; Peller PJ; Wiseman GA
J Comput Assist Tomogr; 2007; 31(5):800-5. PubMed ID: 17895795
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
12. PET in oncology: will it replace the other modalities?
Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
[TBL] [Abstract][Full Text] [Related]
13. The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review.
Patel K; Hadar N; Lee J; Siegel BA; Hillner BE; Lau J
J Nucl Med; 2013 Sep; 54(9):1518-27. PubMed ID: 23776200
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of positron emission tomography in oncology.
Bomanji JB; Costa DC; Ell PJ
Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
[TBL] [Abstract][Full Text] [Related]
15. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
16. Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005.
Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
J Thorac Oncol; 2014 Apr; 9(4):512-8. PubMed ID: 24736074
[TBL] [Abstract][Full Text] [Related]
17. Predictors of patient preference for either whole body magnetic resonance imaging (WB-MRI) or CT/ PET-CT for staging colorectal or lung cancer.
Miles A; Evans RE; Halligan S; Beare S; Bridgewater J; Goh V; Janes SM; Navani N; Oliver A; Morton A; Morris S; Rockall A; Taylor SA;
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):537-545. PubMed ID: 32410378
[TBL] [Abstract][Full Text] [Related]
18. Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies.
Taylor SA; Mallett S; Miles A; Morris S; Quinn L; Clarke CS; Beare S; Bridgewater J; Goh V; Janes S; Koh DM; Morton A; Navani N; Oliver A; Padhani A; Punwani S; Rockall A; Halligan S
Health Technol Assess; 2019 Dec; 23(66):1-270. PubMed ID: 31855148
[TBL] [Abstract][Full Text] [Related]
19. PET-CT in clinical oncology.
Maldonado A; González-Alenda FJ; Alonso M; Sierra JM
Clin Transl Oncol; 2007 Aug; 9(8):494-505. PubMed ID: 17720652
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis.
Wu LM; Chen FY; Jiang XX; Gu HY; Yin Y; Xu JR
Eur J Radiol; 2012 Feb; 81(2):303-11. PubMed ID: 21145680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
